



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism

This is the author's manuscript Original Citation: Availability: This version is available http://hdl.handle.net/2318/1737018 since 2020-04-23T10:59:42Z Published version: DOI:10.1007/s12672-019-00375-0 Terms of use: Open Access Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 MOLECULAR AND ELECTROPHYSIOLOGICAL ANALYSES OF ATP2B4 GENE

2 VARIANTS IN BILATERAL ADRENAL HYPERALDOSTERONISM

Namita Ganesh Hattangady¹, Jessica Foster¹, Antonio Marcondes Lerario¹, Daniela
Ponce-Balbuena², Juilee Rege³, Silvia Monticone⁴, José Jalife², William E. Rainey^{1,4},
Paolo Mulatero³, and Tobias Else¹

Department of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes,
University of Michigan, Ann Arbor, Michigan, USA, ²Center for Arrhythmia Research,
University of Michigan, Ann Arbor, Michigan, USA, ³Department of Molecular and
Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.⁴, Department
of Medical Sciences, Division of Internal Medicine and Hypertension, University of Torino,
Via Genova 3, 10126 Torino, Italy.

12

13	Corresponding author: Dr. Tobias Else, M.D.			
14	Address:	University of Michigan		
15		Department of Internal Medicine		
16		Division of Metabolism, Endocrinology and Diabetes		
17		1150 West Medical Center Drive		
18		Ann Arbor, MI 48109		
19		Email: telse@umich.edu		
20		USA phone: 734-647-7258		
21				

22 ABSTRACT

Primary aldosteronism (PA) is the most common cause of secondary hypertension with a 23 24 high prevalence amongst patients with resistant hypertension. Despite the recent discovery of somatic variants in aldosterone-producing adenoma (APA)-associated PA, 25 causes for PA due to bilateral aldosterone production remain unknown. In this study we 26 identified several rare variants in the ATP2B4 [coding for a Ca-ATPase Pump, PMCA4], 27 in a cohort of patients with bilateral PA. ATP2B4 belongs to the same family of Ca-28 ATPases as ATP2B3, which is involved in the pathogenesis of APA. The ATP2B4 variants 29 were functionally analyzed for effects on aldosterone synthase (CYP11B2) expression 30 and steroid production in basal and agonist-stimulated conditions, and for changes in 31 32 biophysical properties of channel properties. Several in vitro molecular analyses were conducted: 1) Real time quantitative PCR (gPCR) confirmed ATP2B4 mRNA in the 33 34 various tissue including the human adult adrenal gland, APAs, and the human 35 adrenocortical cell line HAC15. 2) Immunohistochemistry indicated PMCA4 expression throughout the adrenal cortex. 3) Knock down of ATP2B4 in HAC15 exhibited reduced 36 37 Angiotensin II-stimulation in one of four shRNA clones. 4) Stable HAC15 cell lines for doxycycline (dox) – inducible wildtype and variant forms of ATP2B4, were generated. Q-38 PCR and immunostaining confirmed dox-induced upregulation of ATP2B4 mRNA and 39 protein. However, increased expression of the PMCA4b variants did not have a significant 40 41 effect on basal or agonist-stimulated CYP11B2 expression. Whole cell recordings in HAC15 cells indicated robust PMCA4b conductance in native cells, but reduced 42 conductance in the WT and variant PMCA4b. The previously defined PA-causing 43 mutation in ATP2B3, also a Calcium ATPase family member, served as a positive control 44

for the same dox-inducible system and exhibited elevated *CYP11B2* mRNA compared with the wildtype variant. In conclusion, while this study did not define a pathogenic role for *ATP2B4* variants in Bilateral Adrenal Hyperaldosteronism (BHA), we describe an approach of WES analysis for familial and sporadic BHA and outline a template for the thorough *in vitro* characterization of gene variants in the pathogenesis of BHA.

50

52 **INTRODUCTION**

Primary aldosteronism (PA) is the most common form of endocrine hypertension and 53 characterized by renin-independent aldosterone excess. PA can be categorized into two 54 55 main subtypes: Bilateral and unilateral disease. PA is most often sporadic, but familial forms have been described. Over the past decade, next generation sequencing has 56 identified somatic variants in aldosterone producing adenoma (APA)-related PA. Thus 57 far, NGS has identified several genetic variants in APAs, including KCNJ5, CACNA1H, 58 CACNA1D, ATP2B3 and ATP1A1 (1-14), as the underlying mechanism of aldosterone 59 excess in APA. While somatic variants in these genes are found in up to 90% of all APAs, 60 and therefore the majority of cases of unilateral aldosterone excess, germline variants in 61 these or other genes are rare, explaining likely less than 5% of all cases with bilateral 62 aldosterone excess (15,16). 63

The currently known germline variants cause a phenotype of bilateral disease, yet with 64 significant variability in terms of severity, penetrance, age of onset and associated 65 symptoms. For instance, mutations in KCNJ5 account for up to 40% of APA-related PA 66 (17,18). However, while the germline variant KCNJ5^{G151E} was associated with a 67 phenotype of hypertension and negligible hyperplasia, a different germline variant at the 68 same locus, KCNJ5^{G151R} exhibited a severe phenotype with massive hyperplasia, 69 requiring bilateral adrenalectomy (9,14). Familial PA due to germline variants in 70 CACNA1D cause a novel phenotype of PA associated with seizures and other 71 neurological abnormalities (11). Finally, most recently, whole exome sequencing, 72 revealed germline variants in the inward rectifying chloride channel CLCN2 in a subgroup 73 of patients with PA (19,20). These patients display bilateral adrenal hyperplasia-related 74

aldosterone excess, and it was classified as Familial Hyperaldosteronism Type II (FH-II).
 However, the *CLCN2* variants have a low prevalence and the cause for aldosterone
 excess in the majority Bilateral Adrenal Hyperaldosteronism (BHA) cases remains
 unexplained.

The vast majority of patients with BHA present as apparently sporadic disease. The 79 80 bilateral nature of the disease, however, suggests a germline genetic predisposition as one putative causative mechanism. Unfortunately, the availability of tissue for detailed 81 analyses is limited as these patients are usually treated medically. Therefore, analysis is 82 largely restricted to germline variants in families with multiple affected members with PA 83 or patients with apparently sporadic PA, assuming pathogenic variants in genes are 84 shared in this population. Using this approach, we identified rare variants in ATP2B4, 85 which encodes the Calcium ATPase, transcript variant 4b (PMCA4b). We analyzed these 86 87 variants through an *in vitro* pipeline involving characterization of gene expression across 88 tissues, analysis of effects of gene knock-down as well as inducible over-expression of the gene variants on cellular mechanisms, LC-MS/MS measurement of steroids and 89 electrophysiological characterization. 90

91

93 **RESULTS**

94 **Clinical Characteristics**

Patient 1 presented with hypertension (Table 1), a serum K of 3.2 mEg/L, elevated 95 aldosterone with suppressed renin (20.4 ng/dL aldosterone, PRA 0.35 ng/mL/h) and an 96 aldosterone to renin ratio of 120.5. Diagnosis of PA was confirmed by the captopril test 97 and bilateral aldosterone excess by adrenal vein sampling. Patient 2, the brother to 98 Patient 1 was also diagnosed with BHA. Whole exome sequencing identified a 99 heterozygous germline variant c. 3152C>A (p.T1051N) (ATP2B4^{C3152A}) in both patients, 100 but not in unaffected family members. Additional rare variants (ATP2B4^{C3158T} and 101 ATP2B4^{G3346A}) in ATP2B4 were identified in two patients with sporadic BAH (clinical 102 103 details in Table 1. All variants occurred in the calmodulin (CaM) binding domain of PMCA4. 104

105

106 ATP2B4 expression in different tissues

In order to evaluate differential expression of *ATP2B4* we surveyed different human tissues. Real time quantitative PCR (RT-qPCR) analyses identified *ATP2B4* expression to be highest in the brain, heart and healthy and pathological adrenal tissues (normal adrenals and APA) (*Figure 1, Panel A*). Within the adrenal gland, the *ATP2B4* transcript was expressed throughout the cortex, without zone specificity (*Figure 1, Panel B*). A similar pattern was observed for the PMCA4b peptide, using immunofluorescence (*Figure 1, Panel C*).

115 Effect of *ATP2B4* knock down in HAC15 cells.

Four clones of short hairpin RNA (shRNA) lentiviruses targeting ATP2B4 were used to 116 117 transduce the HAC15 cell line containing a CYP11B2 promoter driven secreted gaussian 118 luciferase (HAC15-B2Luc) (21). Non-targeted scrambled shRNA was used as a control. Real time gPCR analyses confirmed significant, albeit not complete, knock down of 119 120 endogenous ATP2B4 transcript and protein levels (Figure 2, Panels A and B). Knock down of PMCA4b protein levels was also confirmed using western analysis. Amongst the 121 four clones, only a single clone exhibited reduced angiotensin II (Ang II) stimulation of the 122 123 CYP11B2 promoter. ATP2B4 knock down did not affect basal or agonist (angiotensin II or K⁺-stimulated CYP11B2 promoter activity in the other clones (Figure 2, Panel C). 124

125

126 Effect of ATP2B4 variants in HAC15 cells.

HAC15 cells with doxycycline (dox)-inducible expression of the wildtype (WT) and rare 127 variants of ATP2B4 (PMCA4b) were generated. Dox treatment increased ATP2B4 128 transcript levels by over 5-fold (Figure 3, Panel A). Immunocytochemistry confirmed 129 plasma membrane localization of the expressed protein (Figure 4, Panel B). Expression 130 of the variant ATP2B4^{C3152A} did not increase basal CYP11B2 transcript levels. However, 131 both WT and two of the rare variants (ATP2B4^{C3158T} and ATP2B4^{G3346A}) did increase 132 basal CYP11B2 levels (Figure 3, Panel C). Further detailed analyses including stimulation 133 by agonists Ang II and K suggested a lack of effect of any of the two of the rare ATP2B4 134 variants (Figure 3, Panel D). On the other hand, cells expressing the ATP2B4^{C3152A} variant 135 displayed elevated CYP11B2 expression in K-stimulated conditions. As a positive control, 136

dox-inducible wildtype ATP2B3 (ATP2B3^{WT}) and a previously described pathogenic 137 variant containing the deletion Leu425-Val426 (ATP2B3⁴²⁵⁻⁴²⁶) (22) were expressed in 138 HAC15 cells, using a similar strategy. This is the first ever study to develop and use a 139 dox-inducible model for ATP2B3 characterization. In this model system, incubation with 140 dox induced ATP2B3 transcript levels by ~4-fold (3, Panel E). The ATP2B3^{WT} variant 141 142 decreased CYP11B2 transcript levels, in agreement with previous reports of reduced basal calcium levels in cells over-expressing the gene variant. Furthermore, ATP2B3²⁴²⁵⁻ 143 ⁴²⁶ variant increased basal CYP11B2 levels by ~15-fold, a more potent effect than earlier 144 reports using transient transfection (22). The stimulatory effects of agonists were also 145 enhanced in cells expressing ATP2B3¹⁴²⁵⁻⁴²⁶ compared to ATP2B3^{WT} expressing adrenal 146 cells (Figure 3, Panels F-H). 147

148

149 Effect of ATP2B4 variants on steroidogenesis.

Following the observations of the effect of the ATP2B4 variants on CYP11B2 expression, 150 we evaluated aldosterone production in these cell lines. Basal aldosterone levels were 151 slightly elevated (1.5 \pm 0.12 Fold, Mean \pm S.E.M) in cells expressing ATP2B4^{WT}, while 152 they were unchanged for the variants ATP2B4^{C3158T} and ATP2B4^{G3346A} (Figure 4, Panel 153 A). Agonists Ang II and K stimulated production of steroids (aldosterone, cortisol, 18-154 155 Hydroxycortisol and 18-oxocortisol), when compared to basal, remained unchanged in ATP2B4^{WT} expressing cells, or any of the cell lines expressing the rare ATP2B4 variants 156 (Figure 5, Panels B-D). 157

159 Electrophysiological analyses of *ATP2B4* variants.

A voltage step protocol was used to analyze differences in the biophysical properties of the ATP2B4 pump variants (*Figure 5, Panels A and B*). The endogenous ATP2B4 current in HAC15 cells was very robust. HAC15 cells expressing increased ATP2B4^{WT} had lower current density. Similarly, the density of current of the rare variants were identical to that of ATP2B4^{WT}. The resting membrane potential of adrenal cells expressing the variant forms of ATP2B4 was unchanged.

166 MATERIALS AND METHODS

Next generation sequencing: NGS was conducted in the UM sequencing core using 167 the Illumina 2500. Paired-end reads (FASTQ file) were aligned to the hg19 assembly with 168 Burrows-Wheeler Alignment (BWA) 92. Then, picard-tools were used for sorting and 169 marking the duplicated reads in the resulting BAM files. Variant calling was performed 170 with FreeBayes 93 and low-quality variants (QUAL<20) was discarded. Common variants 171 (MAF>20) were filtered out in our in-house database. The resulting VCF files were then 172 annotated with ANNOVAR 94 and KGGseq 95. The final list of candidate genes was 173 generated after excluding variants that are common in the population (MAF>1), non-174 coding and synonymous. From the resulting list, genes variants were selected if present 175 176 only in the affected family members in each family.

177

178 **Generation of vectors:** The pMM2-hPMCA4b was a gift from John Penniston & Emanuel Strehler (Addgene plasmid # 47759; http://n2t.net/addgene:47759; 179 RRID:Addgene_47759). Wildtype PMCA4b was PCR amplified to include using 180 181 restriction sites Dralll and Xbal at the 5' and 3' ends, respectively. The resultant amplicon was sub-cloned into the shuttle vector pENTR1A-GFP-N2 (FR1) [a gift from Eric 182 183 Campeau & Paul Kaufman (Addgene plasmid # 19364; http://n2t.net/addgene:19364; 184 RRID:Addgene_19364)] (23). The variants of PMCA4b were generated by site directed 185 mutagenesis using the Q5® Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA). The resultant PMCA4b variants were inserted into the lentivector pCLX-186 187 pTF- R1-DEST-R2-EBR65 [a gift from Patrick Salmon (Addgene plasmid # 45952;

http://n2t.net/addgene:45952; RRID:Addgene_45952)] (24). Lentiviruses (~1 x 10^{6} TU/mL) were generated at the University of Michigan Biomedical Vector Core and used for transducing adrenal cells. Similarly, *ATP2B3^{WT}* and the previously described pathogenic variant *ATP2B3^{ΔLeu425-Val426}* (kindly donated by Dr. Sasha Bandulik) (22), were also cloned in to the pCLX-pTF- R1-DEST-R2-EBR65 lentiviral system. These served as controls for the effect of the ATP2B family in adrenal cells.

194

Cell culture and viral transduction of cell lines: The human adrenocortical carcinoma 195 cell line, HAC15, were used as parental cells grown in DMEM:F12 containing 10%CCS, 196 1% ITS and antibiotics (PenStrep and gentamicin), as previously described. 197 Transductions were performed as previously described (25). HAC15 cells were 198 transduced with lentiviruses at a multiplicity of infection of 3, as follows: 2 million cells 199 were plated in a T-75 flask for 24 h, after which they were incubated with fresh GM-Ab 200 201 containing 10 µg/mL polybrene for 2 hours. Cells were then spinnoculated (centrifuged) at 1000 rpm with lentiviruses and GM-Ab with 8 µg/mL polybrene. After overnight 202 incubation, the cells were recovered by the addition of twice the volume of GM-Ab and 203 incubated for additional 24 h. At the end of 48 h from transduction, the cells were 204 incubated in regular GM containing 5 µg/mL blasticidin (mammalian selection marker). A 205 mixed population of blasticidin-selected HAC15 cells were used to analyze gene 206 mutations. The generated cells carried doxycycline-inducible gene expression systems 207 for ATP2B4^{WT}, ATP2B4^{C3152A}, ATP2B4^{C31528T} and ATP2B4^{G3346A}.For experiments, 208 HAC15-dox-ATP2B4 (wildtype or variant cells) were plated in 24-well plates at a density 209 of 200,000 cells/well until 60% confluence. After 48h, cells were starved in 0.1% CCS low 210

serum media (LS) for 24 h and then treated with LS with/without doxycycline (1 µg/mL)
for 72 h for maximal induction of the transgene. Agonists (10 nM Ang II and 18 mM K⁺)
were introduced for the last 12 h. For LC-MS/MS measurement of steroids, cells were
incubated with LS with/without doxycycline and agonists for 72 h. Ang II was replenished
every 24 h due.

216 For knock-down studies, HAC15-B2Luc cells (kindly donated by Dr. Celso Gomez-217 Sanchez) expressing a CYP11B2-driven secreted luciferase were cultured and treated with dox and agonists as described for gene expression studies. These cells have been 218 219 successfully used for functional analysis of the KCNJ5^{T158A} variant in adrenal cells (21). HAC15-B2Luc cells were transduced with four different clones of short-hairpin RNA for 220 ATP2B4 knock-down and selected with puromycin (10 µg/mL). Twenty-five microliters of 221 the media were analyzed for luciferase activity using colentrazine, as described 222 elsewhere (21). 223

For electrophysiological experiments, circular coverslips were coated with 50 µg/mLPoly-D-Lysine for 2 h at room temperature, followed by coating with 1 µg/mL laminin (overnight at 4°C). Coverslips were washed at least three times with 1X PBS and transferred to 24well plates. At the time of patching, HAC15-dox-ATP2B4 cells incubated with doxycycline for 72 h were trypsinized and plated on the coated coverslips at a density of 100,000 cells/well in GM with doxycycline and incubated for 1 h prior to patching.

230

Δ4 Steroid quantitation by liquid chromatography/tandem mass spectrometry (LC MS/MS): A 150 µL aliquot of media from HAC15-dox-ATP2B4 cells, along with 50 µL

internal standard of deuterated steroids, was deproteinated using acetonitrite as previously described (Rege J et al, 2015). Following deproteinization, extraction of $\Delta 4$ steroids was performed using 1 mL methyl-t-butyl ether (MTBE). The organic phase was dried down and concentrated under nitrogen, reconstituted with 50 µL of 1:1 methanol:deionized water and transferred to a 0.25 mL vial insert. The LC-MS/MS assay was performed as previously described (26).

239

240 **Electrophysiology:** Ion currents were recorded in whole-cell patch-clamp configuration using a MultiClamp 700B amplifier and Digidata 1440A digitizer (Molecular Devices, 241 Sunnyvale, CA, USA) as described earlier (25). Patch pipettes had resistances of 5-8 242 MO when filled with intracellular pipette solution and placed in extracellular solution. 243 External solution containing 137 mM NaCl, 5 mM KCl, 5 mM glucose, 1 mM MgCl₂, 1.2 244 mM CaCl₂, and 5mM HEPES (pH 7.4) was perfused through the system. The internal 245 pipette solution contained 95mM K-gluconate, 30 mM KCl, 4.8 mM Na₂HPO₄, 1.2 mM 246 NaH₂PO₄, 5 mM glucose, 2.38 mM MgCl₂, 0.726 mM CaCl₂, 1 mM EGTA, and 3 mM ATP 247 (pH 7.2). Data acquisition and analysis were performed using pCLAMP software 248 (Molecular Devices, Sunnyvale, CA, USA). Normalization of current amplitudes to cell 249 size was performed by dividing amplitudes by cell capacitance (Cm) to generate current 250 251 densities (pA/pF) (25).

252

Immunofluorescence: Slides with 5 µ serial sections of the human adrenal cortex were
deparaffinized. After antigen retrieval in pH 6 citrate buffer and pH 9 Tris buffer

respectively, the sections were incubated for 1 h in primary antibodies for CYP11B2 255 (mouse monoclonal clone 41-17B; 1:100; kindly donated by Dr. Celso Gomez-Sanchez) 256 and PMCA4b (mouse monoclonal clone JA9; Catalog# MA1-914, Millipore; 1:100). After 257 three successive washes in 1X PBS-0.5% Tween (PBS-T), the sections were incubated 258 Alexa Fluor® 647 goat anti-mouse antibody (1:100) for 1 h and with 100 nM DAPI for 5 259 mins. Following washes in 1X PBS-T, coverslips were mounted using the ProLong[™] Gold 260 Antifade Mountant without DAPI (Thermo Fisher Scientific). Sectioned treated with only 261 secondary antibody served as negative controls. An H and E stained section of the 262 263 adrenal was used to identify the zones.

264

265 RNA isolation and gene expression assays: RNA was extracted from tissue or cell lines using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), following manufacturer's 266 recommendations for on-column DNase treatment (RNase-free DNase Kit, Qiagen). Two 267 268 hundred nanograms of RNA were reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA). Real-time 269 quantitative PCR was performed for ATP2B4 (Hs00608066_m1, Thermo Fisher 270 Scientific), CYP11B2 (as previously described in Hattagady et al 2016) and normalized 271 to PPIA (Hs99999904 m1, Thermo Fisher Scientific). Relative quantification of the data 272 was performed using the $2^{-\Delta\Delta Ct}$ method. 273

274 **DISUSSION**

Over the last decade our understanding of the contribution of somatic genetic changes to
APA-related PA has significantly increased. Research on the causes of bilateral disease,
however, has been stymied by the very limited tissue availability due to mainly
pharmacologic treatment of bilateral disease.

279 Herein, we used exome sequencing of germline DNA obtained from patients with BAH in an attempt to identify potential pathogenic gene variants. We focused on three rare 280 variants in *ATP2B4*, which encodes the Ca²⁺ ATPase Pump PMCA4. The mechanistic 281 282 characterization of the variants involved knock down of endogenous ATP2B4 as well as expression of wild type and rare ATP2B4 variants in basal and agonist-stimulated 283 conditions in the human adrenocortical carcinoma cell line (HAC15). The ATP2B4C3152A 284 did not affect CYP11B2 transcript levels or the production of steroids aldosterone, cortisol, 285 18-Hydroxycortisol or 18-Oxocortisol in basal conditions, although a minor increase in K+-286 stimulated aldosterone observed. The ATP2B4^{C3158T} and ATP2B4^{G3346A} variants 287 increased basal CYP11B2 mRNA levels, although not more than the ATP2B4WT 288 transgene itself and far less than an ATP2B3 variant observed in APAs that served as a 289 290 positive control. No changes in current density was observed using electrophysiological analysis. Parallel analysis of a disease-causing variant in ATP2B3 displayed dramatic 291 292 increases of CYP11B2 expression, making it unlikely that the subtle changes observed with ATP2B4 variants are of pathophysiological relevance. Thus, overall, an overt 293 pathogenic role with large increases in aldosterone production was excluded for the 294 ATP2B4 variants. 295

We cannot, however, exclude the possibility that the ATP2B4 variants act in conjunction 296 with other genes or environmental factors that affect aldosterone production. Indeed, the 297 challenge in finding new genetic causes of PA is that any new gene harboring potential 298 pathogenic variants might be associated with low disease penetrance. An example of this 299 phenomenon can be seen in the recent study investigating the role of several unique 300 hereditary CLCN2 gene variants, where at least one large kindred (CLCN2 Arg172GIn) 301 showed incomplete penetrance (20). Similarly, in vitro expression of several CLCN2 302 variants (p.Gly24Asp, p.Tyr26Asn, p.Met22Lys, p.Ser865Arg, p.Arg172Gln) showed 303 304 great variation of their effects on CYP11B2 expression (19,20). Certainly, the incomplete penetrance could be attributed, at least partially, to genomic and epigenomic changes 305 acting as modifiers. 306

The hypothesis of a germline genetic predisposition to PA in BHA is based on the 307 observation of bilateral renin-independent aldosterone production. However, there is also 308 the possibility that a yet to be identified environmental or other pathogenic mechanism 309 contributes to the phenomenon of BHA. To this extent a recent study showed different 310 rare variants in CACNA1D in different aldosterone-producing cell clusters found in the 311 312 same adrenal gland from BAH patients (27). It remains to be shown, whether these multiple somatic mutations could occur by chance or due to an underlying genetic 313 predisposition. 314

In summary, while our study did not identify a pathogenic role of the *ATP2B4* variants, we focused on developing a pipeline for the detailed analyses of gene variants. We successfully demonstrated an efficient lentiviral approach for tight dox-inducible gene expression and the assessment of rare gene variant. Certainly, this system exhibited a

remarkable improvement in the effects of the PA-causing ATP2B3 mutation as compared 319 to previous reports (22). Further, we describe a thorough investigation of these variants 320 including 1) characterization of gene expression across tissues, 2) knock-down analyses 321 of an inactivating gene variant 3) expression of the wildtype and rare gene variant to 322 define their effects on CYP11B2 transcript levels, steroidogenesis by LC-MS/MS, and 4) 323 324 electrophysiological analyses of the biophysical properties of the variants in relation to the wildtype protein. Finally, we would like to emphasize the need to publish not only 325 proven pathogenic genetic causes of BHA but also analysis of rare genetic variants, for 326 327 which experimental data argues against an involvement in the pathogenesis of the disease, even if it is simply to avoid a double effort in the scientific community. 328

329 ACKNOWLEDGEMENTS

We would like to acknowledge Dr. Celso Gomez-Sanchez for his advice on sub-cloning
 strategies and Dr. Sasha Bandulik for generously sharing expression vectors for
 ATP2B3^{WT} and ATP2B3^{Δ425-426}.

333 **FIGURE LEGENDS**

Table 1. A) Rare gene variants in *ATP2B4*; B) Clinical characteristics of patients with
 hereditary or sporadic germline variants in *ATP2B4*.

336

Figure 1. Expression of *ATP2B4* in tissues. (A) Real time analyses of *ATP2B4* transcript
variant 2 in adrenal tissues in comparison with various tissues. *p<0.05 versus pancreas
(B) Zonal expression of *ATP2B4* mRNA across the human adrenal using laser capture
microscopy. (C) Immunofluorescence for PMCA4b protein on serial sections of the human

adrenal cortex: (i) H&E (ii) negative control incubated only with secondary antibody and
DAPI (iii, iv) expression of CYP11B2 and PMCA4b, respectively.

343

Figure 2. Analysis of knock down of *ATP2B4* in adrenal cells. (A,B) Real time analysis demonstrating knock down of *ATP2B4* mRNA and protein in four shRNA clones (-04, -05, -07 and -39) and controls (HAC15-B2Luc and scrambled shRNA). (C) Effect of *ATP2B4* shRNA on agonist stimulation. *p<0.05 versus basal, ^vp<0.05 versus HAC15 Ang II stimulation.

349

Figure 3. Analysis of conditional expression of WT or variant ATP2B4 in adrenal cells. 350 (A, B) Real time analysis demonstrating doxycycline-inducible expression of WT and 351 variant ATP2B4 forms (ATP2B4^{WT/C3152A/C3158T/G3346A}) mRNA and protein in the HAC15 352 adrenal cell line. (C,D) Comparison of the effect of ATP2B4 variants (72 h incubation with 353 1 µg/mL dox) in basal and agonist stimulated (12 h) conditions in HAC15 cells. (E) Real 354 time analysis demonstrating doxycycline-inducible expression of WT and mutant 355 ATP2B3, mRNA as positive controls. (F-H) Comparison of the effect of ATP2B3^{WT} and 356 ATP2B3^{Δ 425-426} (72 h incubation with 1 µg/mL dox) in basal and agonist stimulated (12 h) 357 conditions in HAC15 cells. *p<0.05 versus respective treatment without dox, ^vp<0.05 358 359 versus respective basal.

360

Figure 4. Effect of of WT and variant *ATP2B4* forms on steroid production on HAC15 cells. LC-MS/MS was used to determine the effect of elevated *ATP2B4* variants (*ATP2B4*^{WT/C3152A/C3158T/G3346A}) on steroid production in HAC15 adrenal cells. Amount of

steroid was calculated in pg/mL and normalized to amount of protein per well. Means \pm S.E.M were calculated as fold over respective basals. *p<0.05 versus basals in respective cell lines.

368	Figure 5. Electrophysiological analyses of WT or variant ATP2B4 in HAC15 cells. IV plots				
369	(A) and traces (B) for HAC15 cells expressing endogenous ATP2B4, ATP2B4 ^{WT} ,				
370	ATP2B4 ^{C3152A} , ATP2B4 ^{C3158T} and ATP2B4 ^{G3346A} (n=7-10 for all variants). Internal and				
371	external solutions, and protocols followed were as described in the Materials and Methods				
372	section.				
373					
374					
375	REFERENCES				
376					
377 378 379 380 381 382 383 384 385 386 387 388 387 388 389 390 391 392 393	 Akerstrom T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, Knoefel WT, Saeger W, Feller A, Ip J, Soon P, Anlauf M, Alesina PF, Schmid KW, Decaussin M, Levillain P, Wangberg B, Peix JL, Robinson B, Zedenius J, Backdahl M, Caramuta S, Iwen KA, Botling J, Stalberg P, Kraimps JL, Dralle H, Hellman P, Sidhu S, Westin G, Lehnert H, Walz MK, Akerstrom G, Carling T, Choi M, Lifton RP, Bjorklund P. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7:e41926 Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, O'Shaughnessy KM. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59:587-591 Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45:1055- 1060 Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack 				
393 394 395 396 397 398	4. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45:440-444, 444e441-442				

399 5. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki 400 P, Stratakis CA, Chrousos GP. A novel point mutation in the KCNJ5 gene causing primary 401 hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 402 2012; 97:E1532-1539 403 6. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, 404 Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, 405 Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary 406 hypertension. Science 2011; 331:768-772 407 7. Kuppusamy M, Caroccia B, Stindl J, Bandulik S, Lenzini L, Gioco F, Fishman V, Zanotti G, Gomez-408 Sanchez C, Bader M, Warth R, Rossi GP. A Novel KCNJ5-insT149 Somatic Mutation Close to, but 409 Outside, the Selectivity Filter Causes Resistant Hypertension by Loss of Selectivity for Potassium. 410 J Clin Endocrinol Metab 2014; 99:E1765-1773 8. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, Sterner C, Warth 411 412 R, Mulatero P, Rainey WE. a Novel Y152C KCNJ5 mutation responsible for familial 413 hyperaldosteronism type III. J Clin Endocrinol Metab 2013; 98:E1861-1865 414 9. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, 415 Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth 416 R, Allolio B, Jeunemaitre X, Veglio F, Reincke M. KCNJ5 mutations in European families with 417 nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59:235-240 418 10. Murthy M, Azizan EA, Brown MJ, O'Shaughnessy KM. Characterization of a novel somatic KCNJ5 419 mutation dell157 in an aldosterone-producing adenoma. J Hypertens 2012; 30:1827-1833 420 Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, 11. 421 Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, 422 Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerstrom G, Bjorklund P, Carling T, 423 Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in 424 aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45:1050-1054 425 12. Scholl UI, Stolting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling 426 T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna 427 CB, Trachtman H, Fahlke C, Lifton RP. Recurrent gain of function mutation in calcium channel 428 CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015; 4:e06315 429 13. Daniil G, Fernandes-Rosa FL, Chemin J, Blesneac I, Beltrand J, Polak M, Jeunemaitre X, Boulkroun 430 S, Amar L, Strom TM, Lory P, Zennaro MC. CACNA1H Mutations Are Associated With Different 431 Forms of Primary Aldosteronism. EBioMedicine 2016; 13:225-236 432 14. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley 433 FL, Farhi A, Wang WH, Lifton RP. Hypertension with or without adrenal hyperplasia due to 434 different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012; 435 109:2533-2538 436 15. Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, Miller BS, Giordano TJ, Tomlins SA, 437 Rainey WE. Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White 438 Americans. J Clin Endocrinol Metab 2018; 103:3869-3876 439 16. Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, Thompson LDR, 440 Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T, Giordano TJ, Tomlins SA, Rainey WE. 441 Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension 2019; 442 73:885-892 443 17. Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, 444 Monticone S, Amar L, Meatchi T, Mantero F, Cicala MV, Quinkler M, Fallo F, Allolio B, Bernini G, 445 Maccario M, Giacchetti G, Jeunemaitre X, Mulatero P, Reincke M, Zennaro MC. Genetic

446		spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma.
447		Hypertension 2014; 64:354-361
448	18.	Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV, Pezzani R, Auchus RJ,
449		Ghayee HK, Shibata H, Kurihara I, Williams TA, Giri JG, Bollag RJ, Edwards MA, Isales CM, Rainey
450		WE. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and
451		adrenocortical cells. J Clin Endocrinol Metab 2012; 97:E1567-1572
452	19.	Fernandes-Rosa FL, Daniil G, Orozco IJ, Goppner C, El Zein R, Jain V, Boulkroun S, Jeunemaitre X,
453	-	Amar L, Lefebvre H, Schwarzmayr T, Strom TM, Jentsch TJ, Zennaro MC. A gain-of-function
454		mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 2018;
455		50:355-361
456	20.	Scholl UI, Stolting G, Schewe J, Thiel A, Tan H, Nelson-Williams C, Vichot AA, Jin SC, Loring E,
457		Untiet V, Yoo T, Choi J, Xu S, Wu A, Kirchner M, Mertins P, Rump LC, Onder AM, Gamble C,
458		McKenney D, Lash RW, Jones DP, Chune G, Gagliardi P, Choi M, Gordon R, Stowasser M, Fahlke
459		C, Lifton RP. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet
460		2018; 50:349-354
461	21.	Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium channel
462		mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology
463		2012; 153:1774-1782
464	22.	Tauber P, Aichinger B, Christ C, Stindl J, Rhayem Y, Beuschlein F, Warth R, Bandulik S. Cellular
465		Pathophysiology of an Adrenal Adenoma-Associated Mutant of the Plasma Membrane Ca(2+)-
466		ATPase ATP2B3. Endocrinology 2016; 157:2489-2499
467	23.	Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK,
468		Kaufman PD. A versatile viral system for expression and depletion of proteins in mammalian
469		cells. PLoS One 2009; 4:e6529
470	24.	Giry-Laterriere M, Cherpin O, Kim YS, Jensen J, Salmon P. Polyswitch lentivectors: "all-in-one"
471		lentiviral vectors for drug-inducible gene expression, live selection, and recombination cloning.
472		Hum Gene Ther 2011; 22:1255-1267
473	25.	Hattangady NG, Karashima S, Yuan L, Ponce-Balbuena D, Jalife J, Gomez-Sanchez CE, Auchus RJ,
474		Rainey WE, Else T. Mutated KCNJ5 activates the acute and chronic regulatory steps in
475		aldosterone production. Journal of molecular endocrinology 2016; 57:1-11
476	26.	Rege J, Nishimoto HK, Nishimoto K, Rodgers RJ, Auchus RJ, Rainey WE. Bone Morphogenetic
477	_0.	Protein-4 (BMP4): A Paracrine Regulator of Human Adrenal C19 Steroid Synthesis. Endocrinology
478		2015; 156:2530-2540
479	27.	Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M,
480	_/.	Sasano H, Tomlins SA, Rainey WE. Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.
481		Hypertension 2018; 72:874-880
101		


Table 1. A) Rare gene variants in *ATP2B4*

Gene Name	Nucleotide change	protein change	Frequency (EXAC)	Exon number	Transcript variant affected
ATP2B4	c.C3152A	p.T1051N	0.0015	Exon 20	PMCA4a, PMCA4b
	cC3158T	p.S1052F	0.0081	Exon 20	PMCA4a, PMCA4b
	c.G3346A	p.E1116K	0.0004	Exon 21	PMCA4b only

B) Clinical characteristics of BHA patients with rare ATP2B4 variants

Parameters	Patient 1	Patient 2	Patient 3	Patient 4
ATP2B4 variant	c.C3152A	c.C3152A	c.G3346A	c.C3158T
Serum K⁺ (mEq/L)	3.2	4	3.4	3.4
Aldosterone (ng/dL)	42.2	20.4	47	23.7
PRA (ng/mL/h)	0.35	0.3	0.5	0.4
ARR	120.5	68	94	59.3
Confirmatory test	37 ARR post captopril	10.9 ng/dL Aldosterone post saline load	11.2 ng/dL Aldosterone post saline load	12.1ng/dL Aldosterone post saline load
AVS	BHA	n/a	ВНА	ВАН
Imaging				
Diagnosis	вна	ВНА	ВНА	Micronodule 7 mm left adrenal

Figure 1. Characterization of ATP2B4 expression across tissues







Figure 2. Effect of ATP2B4 knock down in adrenal cells






Figure 3. Characterization of HAC15 cells with dox-inducible ATP2B4 variants




Figure 4. Effect of PMCA4b variants on steroid production





Figure 5. Electrophysiological analyses of ATP2B4 variants



(B)

m٧

-120mV

100 ms